Introduction: CD4
low/-GITR + cells were isolated with magnetic separation, and their phenotype was compared with that of CD4 + CD25 high GITR − cells. Regulatory activity of both cell subsets was tested in autologous and heterologous co-cultures after purification through a negative sorting strategy. 
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to self-antigens, which is followed by the activation and expansion of autoreactive lymphocytes and the deposition of immune complexes with an inflammatory/necrotic phenomenon in different tissues.
Despite central mechanisms of tolerance, some T cells recognizing self-antigens are released into the periphery, and one of the mechanisms used to control these potentially damaging cells is the activity of regulatory T cells (Tregs). Therefore, it has been suggested that autoimmune diseases derive from the functional or numeric imbalance between autoreactive T cells and Tregs [1] [2] [3] [4] . Studies on patients with SLE found that effector T cells are resistant to regulatory activity of Tregs [5, 6] . In addition, either reduced number or impaired function of circulating Tregs in SLE has been also reported [7] [8] [9] [10] [11] . As an apparent paradox, moreover, some studies described an expansion of Tregs in autoimmune diseases, considered as a homeostatic attempt to control activated effector T cells [12] [13] [14] [15] [16] . Thus, conclusive data are still lacking [15, 17] .
Tregs were originally identified by high surface expression of the CD25 molecule (CD25 high ), but further studies indicated that only CD25 high cells expressing the forkhead box protein P3 (FoxP3) transcriptional factor possess regulatory activity [18, 19] . Moreover, regulatory functions can be exerted also by CD4 + CD25 − cells [20, 21] , and in SLE patients, CD4 + CD25 −
FoxP3
+ cells with a regulatory activity have been described [14, 22] .
Other proteins are differentially expressed in Tregs and a number of different Treg subsets, characterized by one or more markers, have been described [23] [24] [25] [26] [27] . Among them, GITR is a marker overexpressed in murine CD4 + Tregs and with apparently contrasting functions. It favors Treg expansion [28] [29] [30] [31] , but, in the short term, it inhibits Treg activity by downregulating FoxP3 [32, 33] . A problem affecting most Treg markers is that they can be expressed by cells devoid of regulatory activity, such as activated effector cells. For example, the value of CD25 as a Treg marker, particularly in tumor and autoimmune diseases, including SLE, has been questioned after the demonstration that CD25 high cells are contaminated by activated effector cells [8, 34, 35] .
Because we recently demonstrated that CD4 
Methods

Study population
Thirty-two patients with SLE, classified according to the American College of Rheumatology criteria [37] , were enrolled, and 25 sex-and age-matched subjects acted as healthy controls (HCs). Twenty-five of 32 patients were women, mean age was 44 ± 11 years, and mean disease duration was 9 ± 7 years. Clinical and serologic records were collected at the time of enrollment, and disease activity was measured by using the SLE disease activity index (SLEDAI) [38] . Sixteen patients were taking hydroxycloroquine, 200 mg/day, five patients were receiving mycophenolate mofetil, 2 g/day, and four patients were taking azathioprine, 150 mg/day. Fifteen patients were also receiving less than 5 mg/day of prednisone. The whole study was approved by the local ethics committee "Comitato Etico delle Aziende Sanitarie Regione Umbria" (CEAS), and written informed consent was obtained in accordance with the Declaration of Helsinki.
Cell isolation
Peripheral blood (PB) mononuclear cells were isolated from heparinized venous blood by gradient separation (Ficoll-Hypaque), and CD4 + T cells were magnetically sorted with negative immunoselection by using human CD4 + isolation kit II and LD columns (Miltenyi Biotec). Purity of CD4 + cells was >98.9%. To perform real-time polymerase chain reaction (PCR), cell subsets were isolated as previously reported [36] . For CD62L evaluation, CD4
6 cell/ml) were activated with PMA (50 ng/ml) and ionomycin (250 ng/ml; Sigma-Aldrich) for 3 days.
To perform functional assays, CD4 + T cells were passed through MACS columns after incubation with Biotin-anti human CD25 and anti-Biotin microbeads. To avoid contaminating CD25
+ cells, flow-through cells were passed once again through MACS column (<1% of cells resulted to be CD25 [39] . Half of flow-through was stained with PE-antihuman-GITR and subsequently with anti-PE microbeads to obtain CD4 + CD25 − GITR − effector cells in the flowthrough (cell purity >99%). GITR-depleted CD4 + cell population (that include effector and CD4 + CD25
high GITR − cells) was obtained similarly, by using anti-GITR Ab instead of anti-CD25 Ab [39] . For intracellular FOXP3 staining, cells were permeabilized, fixed, and stained with anti-human FOXP3-AF647 (BD Pharmingen) by following the manufacturer's instructions. To perform CTLA-4 staining, cells were cultured with PMA, ionomycin, and monensin for 4 hours at 37°C, permeabilized with saponin buffer, and incubated with PE-anti-human CTLA-4 (BD Pharmingen) [36] .
Samples were analyzed by using Beckman Coulter EPICS XL-MCL flow cytometer running EXPO32 ADC analysis software and BD Facscalibur running BD CellQuest Pro analysis software.
Real-time PCR
Total RNA was isolated with the RNeasy Mini extraction kit (Qiagen), and RNA was reverse transcribed with Quantitect reverse transcription kit (Qiagen). Real-time PCR was performed in a Chromo 4 Four-Color RealTime System (Bio-Rad) using Taqman probes (Applied Biosystems). The VIC-labeled housekeeping gene, hypoxanthine phosphoribosyl transferase 1 (HPRT)-1, was amplified in the same tube of the FAM-labeled investigated gene (four replicates). The ΔΔCt method was used to determine expression of the gene of interest, and the expression of effector cells were set equal to 1 [39] . Transwell experiments were performed in 24-well Transwell plates with a 0.4 mm pore size (Corning). TCR activation was obtained by coating the bottom and the top chambers of the Transwell plates by crosslinked goat anti-mouse mAb (Southern Biotech) and mouse anti-human CD3ε [36] . CFSE-labeled effectors were seeded in the bottom chamber of the 24-well plate at a concentration of 0.5 × 10 5 cells/well. The unlabeled cells (effectors, CD25-depleted or GITR-depleted CD4 + cells) were plated in the top chamber of the transwell at 1.5 × 10 5 cells/well. CFSE dilution was evaluated after 4-day culture with FACS analysis after TCR stimulation [36] . Regulatory activity of CD4 + CD25 low/-GITR + and CD4 + CD25
high GITR − cells was calculated by comparing cell proliferation rate of effector cells co-cultured with effector cells with that of effectors co-cultured with CD25-depleted or GITR-depleted CD4 + cells, respectively, as previously described [36] .
Statistical analysis
Mann Whitney U test was used to compare HC and SLE patients. Kruskal-Wallis test with Dunn's test for multiple comparison post hoc were used for the comparison between HC, active SLE, and inactive SLE. Spearman correlation coefficient, χ 2 test, and binary logistic regression were also used, as detailed throughout the manuscript. The significance level was two-sided and set at P <0.05. All data analysis was performed by using IBM-SPSS version 13.0. 
Results
CD4
GITR
+ cells in SLE, we wondered whether they could be somehow related to general disease activity. To this purpose, patients were divided into two groups according to SLEDAI score: inactive disease patients with SLEDAI =0 (n =13) and active-disease patients with SLEDAI >0 (n =19). As shown in Figure 2D , inactive patients had a percentage of PB CD4 + CD25
low/-GITR + cells higher than those in active patients, whereas the CD4 + CD25 high GITR − Treg percentage was low, irrespective of disease activity ( Figure 2E ). Spearman correlation coefficient or binary logistic regression was used to identify a possible relation between CD4 [43, 44] . Figure 3 shows that in HC, the mRNA levels of CD62L were comparable in untreated naïve effector, CD4 + CD25 low/-GITR + and CD4 + CD25 high GITR − cells and much lower (about ten fold) in PHA/ionophore-activated effectors. In SLE patients, the mRNA levels of CD62L were comparable in effector and CD4 Figure 4E,F) suggest that the memory phenotype of both subsets is more predominant in SLE patients than black column, CD25 low/-GITR + ) is shown as fold increase of mRNA levels in the positively sorted subpopulations over mRNA levels in effector (CD4 + CD25 − GITR − ) T cells, arbitrarily set equal to 1. Data shown are mean ± SD of four SLE patients. ***P <0.001.
in HC [36] . Interestingly, CD127 expression levels in CD4 + CD25 low/-GITR + cells ( Figure 4G ) were lower than those observed in HC [36] . 
+ cells from SLE patients exert regulatory activity on the proliferation of the respective autologous effectors at levels as similar as those seen in HC ( Figure 5A-C) , confirming that they are Tregs. Figure 5C shows that the mean regulatory activity by CD4 + CD25 low/-GITR + cells from SLE patients was higher than that exerted by the same cells from HC, but the difference was not significant. Not always did CD4 + CD25 high GITR − cells from SLE patients exert a regulatory activity on the proliferation of the respective autologous effectors ( Figure 5B), and their regulatory activity was significantly lower than in HCs (Figure 5D ), confirming functional differences between this subset in SLE patients and HCs. Figure 5 ). Data deriving from all patients and HCs is summarized in Figure 8 .
Comparison between Figure 8D and C suggests that SLE CD4 
+ cells over HC effectors had a higher regulatory activity than over SLE effectors, in accordance with the partial resistance to suppression of SLE effectors [5, 6] . Although some studies suggest that the regulatory activity is more active toward autologous effectors, the comparison between Figure 8D and B suggests that SLE CD4 + CD25 low/-GITR + cells had a slightly higher regulatory activity over HC effectors than SLE effectors, again confirming the partial resistance to suppression of SLE effectors. Nevertheless, SLE CD4 + CD25 low/-GITR + cells are more active than HC ones in autologous suppression assay ( Figure 8B and A) .
We low/-GITR + cells was higher in SLE patients (though not significantly different) than in HCs. Taking into account that CD4 + CD25 low/-GITR + cells in SLE are in greater number than in HCs, even their regulatory activity may appear stronger, accordingly (see Figure 7D) . Therefore, the levels of regulatory activity of CD4 [48, 49] . The hypothesis is in line with the possibility that effector T cells are partly activated in autoimmune diseases [5, 6] , thus eliciting Treg activation. In summary, our data overall demonstrate that Figure 5 ) and heterologous (see Figure 7) co-cultures is shown (A-D). **P <0.01 and ***P <0. − , as assessed by flow cytometry. CD25 low means that their CD25 expression level was higher than in effector cells, as shown by both real-time PCR and flow cytometry [36] . These data were confirmed also in cells from SLE patients, as shown in Figure 1 [14] , whereas Zhang et al. [22] do not confirm these findings. As suggested by Horwitz [51] , these differences may depend on the evaluated patient. Indeed, Zhang et al. studied untreated new-onset SLE patients whereas Bonelli et al. and we studied patients with longstanding disease.
The idea that autoimmune diseases derive from functional or numeric imbalance between autoreactive T cells and Tregs is well established. It has been demonstrated that the CD4 + CD25 high cells are less active and/or less frequent in SLE patients [7] [8] [9] [10] [11] , as confirmed by the present study. Nevertheless, Tregs contribute, at least in part, to the control of the disease, as demonstrated by unmasking autoreactive CD4 + T cells with the removal of Tregs [52] . In this setting, it has been hypothesized that subsets of Tregs may arise under specific autoimmune conditions as an effort to counteract the activity of effectors leading to autoimmunity [15] . This hypothesis seems to be confirmed by recent studies describing the expansion of Treg subsets in SLE [12, 14, 16, 50] 
FoxP3
+ cells found by Bonelli et al. [14] in active SLE was associated with defective Treg function of these cells, thereby suggesting a possible contamination with nonTreg cells [14] . Similarly, the Treg cells identified as CD45RA + FoxP3 low by Pan et al. [13] were expanded in active SLE but with a defective suppressive activity [13] . Finally, the in vitro evaluation of regulatory activity of FoxP3 + Helios + Treg cells, increased in SLE and positively correlated to disease activity, was not feasible for technical problems [16] .
When transferring the concept of Tregs from rodents to humans, an important issue was the inability to easily identify human functional Tregs in patients with various autoimmune diseases. For example, it is known that only a subset of T cells identified as CD4 +
CD25
high by flow cytometry are functionally suppressive Tregs, whereas others are activated effector T cells [35, 53] . In SLE patients, the contamination of CD25 high subset with a more activated/autoreactive cells is confirmed by both phenotypic and functional studies. In fact, CD25 high cells expressing FoxP3 are in a lower percentage than in HCs [34] . Moreover, CD25
high cells display an activated phenotype [5, 10] and have a decreased regulatory activity [8] [9] [10] It has been hypothesized that an increased number of fully active Tregs could revert the imbalance of suppressor/effector cell ratio and may change the natural history of autoimmune diseases. Indeed, therapies that increase Treg numbers and activity have been shown to be effective at reversing autoimmune diseases in animal models such as experimental autoimmune encephalitis [54] and diabetes [55] . Of note, ex vivo expanded regulatory T cells, adoptively transferred in lupus-prone mice, reduced the rate of renal disease development, and a second transfer, in animals that already developed proteinuria, further delayed the progression of renal disease and significantly improved survival [56] . Moreover, a single transfer of TGF-β-conditioned T cells to animals decreased circulating antidsDNA Abs, reduced proteinuria, and doubled survival [57] . A phase I/II trial using Tr1 cell clones in patients displaying severe Crohn disease, yielded encouraging results [58] and a dose-escalation trial using autologous ex vivo expanded polyclonal Tregs (CD4 + CD25 + CD127 -/lo ) in diabetes patients is currently ongoing [59] .
We believe that in vitro expanded autologous/ heterologous Tregs may help treat autoimmune diseases, including SLE, and that CD4 + CD25
low/-GITR + cells are interesting from this point of view, because they appear to be a homeostatic attempt to counteract the disease. Protocols to expand CD4 + CD25 low/-GITR + cells are under study and may include TCR/GITR co-triggering or TCR/CD28 co-triggering in the presence of immunosuppressive drugs.
Conclusions
In conclusion, the present data, together with those previously published on patients with primary Sjӧgren syndrome [39] , suggest that CD4 + CD25 low/-GITR + cells are expanded pTregs in response to an effector/Treg imbalance and are able to control, at least in part, the disease. In SLE patients, the CD4 + CD25 low/-GITR + subset does not appear to be contaminated by activated cells devoid of regulatory activity, suggesting that GITR could be used as valuable surface marker of Tregs. Strategies aimed to expand the CD4 + CD25 low/-GITR + subset for therapeutic purposes deserve to be investigated.
